LUMC

Sapreme Appoints CEO, BoD Chair and SAB to Advance Development of Next-Generation RNA Therapeutics for Genetically Driven Diseases

Retrieved on: 
화요일, 5월 28, 2024
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, MSD, Medical laboratory, University College Dublin, Self-publishing, Whitehead Institute, Drug development, Molecular medicine, Vaccine, Genetics, RNA, Therapy, Infection, ALS, Free University, Saponin, MIT, MD, MB, Organon, Master of Science, Clinical chemistry, LUMC, Protein, Asos, Duchenne muscular dystrophy, Medicinal chemistry, Psychiatry, Neurology, Complex conjugate, EAN, SAB, Peptide, Damme, Patient, Doctor of Philosophy, Organization, Free University of Berlin, University, Schering-Plough, Leiden University, DMD, Growth, Spacecraft, Cancer, Leiden University Medical Center, Pharmaceutical industry

Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).

Key Points: 
  • Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).
  • Before joining Sapreme, he was CEO of Byondis (formerly Synthon Biopharmaceuticals), a clinical-stage biopharmaceutical company developing Antibody-Drug Conjugates (ADCs) targeting intractable cancers and auto-immune diseases.
  • During his time at Byondis, Dr. Timmers also served as Chief Scientific Officer, guiding the company’s clinical strategies and growth.
  • I look forward to working with the team at Sapreme to further advance this innovative platform and accelerate our pipeline of RNA therapeutic candidates addressing a range of genetically driven diseases,” said Marco Timmers, Chief Executive Officer of Sapreme.

MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

Retrieved on: 
목요일, 3월 7, 2024
Therapy, CNRS, Target, Newcastle University, Facial muscles, Biotechnology, Professor, Teaching hospital, SAB, Neuromuscular disease, Ageing, Leiden University Medical Center, HD, DMD, Duchenne muscular dystrophy, Inflammation, LUMC, Mitochondrion, Gene therapy, Scientific method, Genetics, Knowledge, Leibniz Association, Publication, Translational research, Respiratory disease, Research, COPD, Pharmaceutical industry

OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.

Key Points: 
  • OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “We are thrilled to welcome Dr.
  • Le Guiner, Dr. Filipovic, Professor Hansbro, and Professor Aartsma-Rus, to our Scientific Advisory Board.
  • She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University.

Sila Realty Trust, Inc. Completes Acquisition of Burr Ridge Medical Office Building for $59.95 Million

Retrieved on: 
목요일, 9월 28, 2023
Hospitals, Construction & Property, Health, REIT, Bed, Speech, Foot, Rehabilitation, Radiology, Ambulatory care, Hospital, Acquisition, Ophthalmology, Cardiology, LUMC, Neurology, Trinity Health, Loyola University Medical Center

Sila Realty Trust, Inc. (the “Company”), a net lease real estate investment trust focused on investing in high quality healthcare properties across the continuum of care, today announced the acquisition of a 104,912 square foot medical office building located in Burr Ridge, Illinois (the “Burr Ridge Healthcare Facility”) for $59.95 million.

Key Points: 
  • Sila Realty Trust, Inc. (the “Company”), a net lease real estate investment trust focused on investing in high quality healthcare properties across the continuum of care, today announced the acquisition of a 104,912 square foot medical office building located in Burr Ridge, Illinois (the “Burr Ridge Healthcare Facility”) for $59.95 million.
  • The Burr Ridge Healthcare Facility is fully leased to Loyola University Medical Center (“LUMC”), a nationally ranked academic health system based in Chicago’s suburbs, which is part of the third largest metropolitan statistical area in the United States.
  • The Burr Ridge Healthcare Facility was purpose built for LUMC, and benefits from its proximity to LUMC’s three affiliated hospitals, including the flagship Loyola University Medical Center with 547 licensed beds.
  • The three-story building is situated on a 6.9-acre lot and is well located, approximately 20 miles southwest of downtown Chicago.

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

Retrieved on: 
금요일, 7월 28, 2023
Xylazine, University, Naloxone, Leiden University Medical Center, Tennessee Bureau of Investigation, Opioid overdose, Research, Doctor of Philosophy, ADMP, Parent, Trial of the century, Incidence, MD, Drug, Poisoning, Hypoventilation, Patient, Hearing, SAN, FDA, LUMC, Regulation of tobacco by the U.S. Food and Drug Administration, Fentanyl, Food, Anesthesiology, Pharmaceutical industry, Anesthesia, Adamis

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.

Key Points: 
  • SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
  • The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University.
  • Dr. Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses.
  • Samuel P. Chapman, Director of Parents for Safer Children, stated, “Prescription strength ZIMHI is the best remedy available for opioid overdose.

IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

Retrieved on: 
목요일, 6월 15, 2023
COCIR, Delft University of Technology, Thermosome, University Medical Center Utrecht, Sarcoma, VU, ETH, University Medical Center, Newcastle upon Tyne Hospitals NHS Foundation Trust, Cancer, Lung cancer, JU, MedTech Europe, Research, Immunotherapy, Teaching hospital, Liver cancer, NYSE, Turku University Hospital, EFPIA, MRI, Radboud University Medical Center, Radiation, Philips, Vrije Universiteit Amsterdam, IHI, Doxorubicin, Interventional oncology, AEX, Liver, Diagnosis, PHG, Death, LUMC, EuropaBio, Pharmaceutical industry, Medical imaging, European, Pfizer

The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry partners

Key Points: 
  • The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry partners
    The consortium will carry out research into improving clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas
    Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the Philips-coordinated IMAGIO consortium [1] of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners [2], to carry out research into less invasive cancer treatments.
  • Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas.
  • In Europe about 2.7 million people are diagnosed with cancer each year [3].
  • This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112053.

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Retrieved on: 
목요일, 4월 27, 2023
Vaccine, Infection, SLP, Leiden University Medical Center, SARS-CoV-2, B.V, Immunotherapy, Person, Patient, Immune system, Cancer, ISA, Mouse, Immunodeficiency, Therapy, LUMC, CHDR, CIMT

ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.

Key Points: 
  • ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.
  • These are demonstrable ex vivo in peripheral blood mononuclear cells (PBMCs) from convalescent donors who recovered from SARS-CoV-2 infection.
  • The data support further development of ISA106 for the protection of immunocompromised people for whom currently approved SARS-CoV-2 vaccines are insufficiently protective."
  • If you would like to meet with ISA Pharmaceuticals at the above event, please contact us at [email protected] .

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Retrieved on: 
목요일, 4월 27, 2023
Vaccine, Infection, SLP, Leiden University Medical Center, SARS-CoV-2, B.V, Immunotherapy, Person, Patient, Immune system, Cancer, ISA, Mouse, Immunodeficiency, Therapy, LUMC, CHDR, CIMT

ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.

Key Points: 
  • ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.
  • These are demonstrable ex vivo in peripheral blood mononuclear cells (PBMCs) from convalescent donors who recovered from SARS-CoV-2 infection.
  • The data support further development of ISA106 for the protection of immunocompromised people for whom currently approved SARS-CoV-2 vaccines are insufficiently protective."
  • If you would like to meet with ISA Pharmaceuticals at the above event, please contact us at [email protected] .

The Inner Circle Acknowledges, Julie Lynn Fitzgerald, MD, FAAP as a Most Trusted Healthcare Professional in the Medical Field

Retrieved on: 
금요일, 4월 7, 2023
Bachelor, Society, University, Pediatrics, Bed, Elective surgery, Society of Critical Care Medicine, Critical Care Medicine (journal), Burn center, Nephrology, Pediatrics (journal), Cancer, Disease, American Academy, Loyola University Medical Center, Multimedia, Mentorship, Loyola University, Disorder, Inner circle, Villanova University, FAAP, Association of American Medical Colleges, Stritch School of Medicine, Patient, Ophthalmology, Gambat Liver Transplant Center, Cardiology, LUMC, Family, Medical specialty, Injury, Nursing, Dentistry, MD, Medicine

BURR RIDGE, lll., April 7, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Julie Lynn Fitzgerald, MD, FAAP, is acknowledged as a Most Trusted Healthcare Professional in the Medical Field.

Key Points: 
  • BURR RIDGE, lll., April 7, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Julie Lynn Fitzgerald, MD, FAAP, is acknowledged as a Most Trusted Healthcare Professional in the Medical Field.
  • Dr. Fitzgerald earned a Bachelor's degree at Villanova University and completed her medical degree (M.D.)
  • Dr. Fitzgerald is a practicing pediatrician and critical care physician who cares for young patients at Loyola University Medical Center (LUMC) in Maywood, IL.
  • According to Dr. Fitzgerald, pediatricians typically work with infants, children, teenagers, and young adults up to the age of 21.

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Retrieved on: 
금요일, 11월 4, 2022
Holm–Bonferroni method, Subclinical infection, Immune tolerance, Ageing, Asthma, Infection, Chronic kidney disease, DFU, Idiopathic pulmonary fibrosis, Pakistan Library Automation Group, Ethics, Internal medicine, Cytokine release syndrome, FDA, Safety, Incidence, ASX, Potency (pharmacology), Sepsis, Ulcer, Therapy, Leiden University Medical Center, Stem cell, Graft-versus-host disease, Acute respiratory distress syndrome, Transplant, Microsoft, Kidney transplantation, Regenerative medicine, US, MCA, Clinical trial, LUMC, MSC, Risk, Efficacy, Kidney, Survival, Patient, Osteoarthritis, Cancer, Department, Dialysis, Pharmaceutical industry, Dentistry

MELBOURNE, Australia, Nov. 4, 2022 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.

Key Points: 
  • Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis.
  • The clinical trial, entitled the "Safety and Efficacy of iPSC-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients - the Nereid Study", will be led by Prof.
  • "This exciting new collaboration follows very promising clinical trial data with MSCs published by Professor Rabelink[1] and our own published pre-clinical data[2] in organ transplant rejection.
  • The consistency and potency of Cynata's unique iPSC-derived Cymerus MSCs make them an ideal candidate for this clinical trial."

Julie Lynn Fitzgerald, MD, FAAP is recognized by Continental Who's Who

Retrieved on: 
목요일, 11월 3, 2022
Pediatrics, Disorder, Elective surgery, III, Loyola University, FAAP, Cardiology, Multimedia, Burn center, American Academy, Loyola University Medical Center, Association of American Medical Colleges, Stritch School of Medicine, Critical Care Medicine (journal), Continental, Society of Critical Care Medicine, Patient, University, Pediatrics (journal), Family, Mentorship, Villanova University, Injury, LUMC, Bachelor, Ophthalmology, Bed, Disease, Society, Association, Nephrology, Cancer, Medical specialty, Medicine, MD

BURR RIDGE, III., Nov. 3, 2022 /PRNewswire/ -- Julie Lynn Fitzgerald, MD, FAAP, is being recognized by Continental Who's Who as a Distinguished Healthcare Professional in the Medical Field, acknowledging her excellence with Loyola University Medical Center.

Key Points: 
  • BURR RIDGE, III., Nov. 3, 2022 /PRNewswire/ -- Julie Lynn Fitzgerald, MD, FAAP, is being recognized by Continental Who's Who as a Distinguished Healthcare Professional in the Medical Field, acknowledging her excellence with Loyola University Medical Center.
  • Dr. Fitzgerald is a practicing pediatrician and critical care physician who cares for young patients at Loyola University Medical Center (LUMC) in Maywood, IL.
  • As a pediatrician and critical care physician, she diagnoses and treats life-threatening infections, injuries, diseases, and other disorders in children.
  • According to Dr. Fitzgerald, pediatricians typically work with infants, children, teenagers, and young adults up to the age of 21.